HASBROUCK HEIGHTS, N.J., May 15, 2009 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) announced today its financial results for the first quarter of 2009. Nymox reported a net loss of $1,004,259, or $0.03 per share for the quarter ending March 31, 2009, compared to $1,347,116, or $0.05 per share for same period in 2008. Net losses include stock compensation charges of $309,650 in 2009 and $204,680 in 2008.The decrease in net losses is attributable to reduced clinical trial expenditures compared to 2008. Product sales amounted to $96,226 for the first quarter of 2009, compared to $104,484 for the same period in 2008. The weighted, diluted average number of common shares at March 31, 2009 was 30,253,246, compared to 29,462,138 at March 31, 2008.
